Alembic Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on May 06, 2025.
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.5 pts less than Nifty Microcap 250 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The board met on May 6, 2025 and approved audited results for Q4 and FY25. Consolidated revenue from operations rose about 7% YoY to Rs. 6,672.08 cr, but consolidated profit after tax slipped to Rs. 583.42 cr from Rs. 615.82 cr. Standalone performance was weaker, with PAT falling around 24% to Rs. 503.12 cr as higher material and employee costs pushed down operating margin to 15.74% from 17.53%. The board recommended a dividend of Rs. 11 per share (550% on Rs. 2 face value), unchanged from the previous year. Statutory auditor K.C. Mehta & Co. LLP will be replaced by KKC & Associates LLP for a five-year term from FY26, and the auditor's report carries an unmodified opinion. An exceptional gain of Rs. 12.87 cr from the final Sikkim flood insurance settlement was recognised.
A maintained dividend and revenue growth are positives, but weaker standalone profits and margin compression are likely to temper near-term sentiment. The auditor change is a routine end-of-term rotation, not a concern.